Abuse of Process Clarified by Canadian Federal Court of Appeal

June 26, 2009

Tags:

Advertising and Marketing Intellectual Property Intellectual Property Litigation Patents Pharmaceuticals

Related Expertise

Related Insights

Déjà vu: PMPRB asserts jurisdiction over Galderma’s drug, Differin
Federal Court on amended Patented Medicines Regulations: new pricing factors and new basket of comparison countries are in; rebate reporting is out
Delay in Canada’s drug pricing reforms to 2021
Pause on PMPRB reform: implementation of new pricing regulations delayed to 2021
Torys Business Brief: A turning point for Canada’s life sciences

Back